0001209191-21-056163.txt : 20210915 0001209191-21-056163.hdr.sgml : 20210915 20210915161238 ACCESSION NUMBER: 0001209191-21-056163 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210913 FILED AS OF DATE: 20210915 DATE AS OF CHANGE: 20210915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hayden Michael R CENTRAL INDEX KEY: 0001352908 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39781 FILM NUMBER: 211255557 MAIL ADDRESS: STREET 1: C/O ASPREVA PHARMACEUTICALS CORPORATION STREET 2: 1203-4464 MARKHAM STREET CITY: VICTORIA STATE: A1 ZIP: V8Z 7X8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbCellera Biologics Inc. CENTRAL INDEX KEY: 0001703057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 BUSINESS PHONE: (604) 559-9005 MAIL ADDRESS: STREET 1: 2215 YUKON STREET CITY: VANCOUVER STATE: A1 ZIP: V5Y 0A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-13 0 0001703057 AbCellera Biologics Inc. ABCL 0001352908 Hayden Michael R C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 2021-09-13 4 M 0 270000 17.73 A 1273397 I See footnote Common Shares 118245 I By spouse Share option (right to buy) 0.32 2021-09-13 4 M 0 270000 0.00 A 2029-09-11 Common Shares 270000 270000 I See footnote These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. /s/ Tryn Stimart, attorney-in-fact 2021-09-15